1-20 of 35
Sort by
News

Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma

Published: 2021
View News titled, Clarithromycin Improves Responses But Fails to Prolong Survival in Newly Diagnosed Myeloma
News

DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma

Published: 2021
View News titled, DDGP Versus SMILE: Comparing Regimens for Extranodal Natural Killer T-Cell Lymphoma
News

Zanubrutinib Active in Patients with Treatment-Naive Del17p CLL/SLL

Published: 2021
View News titled, Zanubrutinib Active in Patients with Treatment-Naive Del17p CLL/SLL
News

How Science Informs Advocacy

Published: 2021
View News titled, How Science Informs Advocacy
News

Adding Isatuximab to Dexamethasone-Pomalidomide Combination Improves Progression-Free Survival in Pretreated Myeloma

Published: 2021
View News titled, Adding Isatuximab to Dexamethasone-Pomalidomide Combination Improves Progression-Free Survival in Pretreated Myeloma
News

Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?

Published: 2021
View News titled, Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?
News

Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma

Published: 2021
View News titled, Daratumumab-Based Induction and Response-Adapted Consolidation Induces MRD Negativity in Patients With Newly Diagnosed Myeloma
News

Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL

Published: 2021
View News titled, Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL
News

Extinguishing Smoldering Myeloma?

Published: 2021
View News titled, Extinguishing Smoldering Myeloma?
News

Is Chemoimmunotherapy for Upfront CLL on Life Support?

Published: 2021
View News titled, Is Chemoimmunotherapy for Upfront CLL on Life Support?
News

Reader Responses: What is the best consolidation therapy for this patient with primary central nervous system lymphoma?

Published: 2021
View News titled, Reader Responses: What is the best consolidation therapy for this patient with primary central nervous system lymphoma?
News

Peripherally Inserted Central Catheters Sharply Increase Risk of Childhood VTE Events

Published: 2021
View News titled, Peripherally Inserted Central Catheters Sharply Increase Risk of Childhood VTE Events
News

Maintenance of Certification: An Update on ABIM’s Evolving Requirements

Published: 2021
View News titled, Maintenance of Certification: An Update on ABIM’s Evolving Requirements
News

Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL

Published: 2021
View News titled, Study Examines Trends in Real-World Treatment Sequencing Patterns for CLL/SLL
News

Study Finds No Benefit With Post-Induction Treatment Intensification in Children With ALL

Published: 2021
View News titled, Study Finds No Benefit With Post-Induction Treatment Intensification in Children With ALL
News

Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting

Published: 2021
View News titled, Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting
News

Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive B-Cell Non-Hodgkin Lymphomas

Published: 2021
View News titled, Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive B-Cell Non-Hodgkin Lymphomas
News

Avadomide Shows Promising Clinical Activity and Tolerability in Relapsed/Refractory DLBCL

Published: 2021
View News titled, Avadomide Shows Promising Clinical Activity and Tolerability in Relapsed/Refractory DLBCL
News

Editor's Corner: The China Conundrum

Published: 2021
View News titled, Editor's Corner: The China Conundrum
News

David H. Koch Center Opens at MSKCC, Sidney Kimmel Welcomes Usama Gergis, and more

Published: 2021
View News titled, David H. Koch Center Opens at MSKCC, Sidney Kimmel Welcomes Usama Gergis, and more